Suppr超能文献

A 4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG.

作者信息

Hartleben-Matkin Curt, Prada Diddier, Mancilla-Vences Rafael

机构信息

Glaucoma Service, Instituto de Oftalmología Fundación Conde de Valenciana, Mexico City 06800, Mexico.

Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología de México, México City 14080, Mexico ; Departamento de Informática Biomédica, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), México City 04510, México ; Laboratory of Environmental Epigenetics, Harvard School of Public Health, Boston, MA 02115, USA.

出版信息

Int J Ophthalmol. 2014 Apr 18;7(2):330-4. doi: 10.3980/j.issn.2222-3959.2014.02.25. eCollection 2014.

Abstract

AIM

To evaluate the long-term response to the fixed combination of dorzolamide/timolol in patients with primary open angle glaucoma (POAG) and the addition of other intraocular pressure (IOP) lowering medications such as prostaglandin analogs and brimonidine.

METHODS

A retrospective, non-randomized, and descriptive clinical study was performed with 182 eyes diagnosed with POAG. Patients were divided into three groups: a group with fixed combination of dorzolamide/timolol only, a second group with prostaglandin analogs plus fixed combination of dorzolamide/timolol, and a third group with the addition of brimonidine to the same fixed combination. IOP data were gathered retrospectively and the differences between groups were calculated.

RESULTS

IOP was reduced satisfactorily in all three groups; however, a progressive IOP reduction was noted in the group with the fixed combination plus prostaglandin analogs. In this group, a progressive, significant and more homogeneous response of the reduction was noted in comparison with the other groups.

CONCLUSION

IOP reduction was efficacious in all three groups. The addition of prostaglandin analogs showed progressive IOP reduction, progressive response and absence of long-term drift. Brimonidine did not show a significant additive effect.

摘要

相似文献

1
A 4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG.
Int J Ophthalmol. 2014 Apr 18;7(2):330-4. doi: 10.3980/j.issn.2222-3959.2014.02.25. eCollection 2014.

本文引用的文献

1
Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.
Expert Opin Pharmacother. 2010 Apr;11(6):959-68. doi: 10.1517/14656561003667540.
5
Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects.
Prog Brain Res. 2008;173:3-14. doi: 10.1016/S0079-6123(08)01101-1.
7
Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mm Hg.
J Glaucoma. 2005 Aug;14(4):267-70. doi: 10.1097/01.ijg.0000169389.09804.33.
8
Is addition of a third or fourth antiglaucoma medication effective?
J Glaucoma. 2004 Apr;13(2):130-6. doi: 10.1097/00061198-200404000-00008.
9
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Arch Ophthalmol. 2002 Oct;120(10):1268-79. doi: 10.1001/archopht.120.10.1268.
10
The impact of ocular blood flow in glaucoma.
Prog Retin Eye Res. 2002 Jul;21(4):359-93. doi: 10.1016/s1350-9462(02)00008-3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验